By Pardis Technology Park company:
Ibrutinib tablets for the treatment of lymphoma cancer were produced by Zist Takhmir Company, one of the member companies of Pardis Technology Park.
CEO of Zist Takhmir Company Sahar Bahmani said that ibrutinib tablets have recently been introduced as an alternative to unsuccessful treatments for patients with lymphoma, and this type of treatment is also used in the country.
In addition to the production of medicine, the production of the active ingredient of this tablet is also on the agenda of the company and within the next few months, the production line of its active ingredient will also start in this company, she said.
With the introduction of this product, the domestic need for this drug will be eliminated, and about $10 million will be saved, she added.
TIM 2022
The first steering council meeting of TIM 2022 was held
Secretary General of D8 Organization said:
Using Update Technologies is the Only Way to Achieve Sustainable Economic Growth in D8 Development

Aiming to develop Iran-Uzbekistan cooperation
Pardis Technology Park, Yashnabad Technology Park Ink Mou on Technological Cooperation
Along with unveiling of 5 pharmaceutical products of a member company of Pardis Technology Park;
Iran’s President visits Pardis Technology Park